Market closed
Nuvalent/$NUVL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nuvalent
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Ticker
$NUVL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
127
Website
Nuvalent Metrics
BasicAdvanced
$5.4B
-
-$3.50
1.33
-
Price and volume
Market cap
$5.4B
Beta
1.33
52-week high
$104.04
52-week low
$61.80
Average daily volume
518K
Financial strength
Current ratio
23.071
Quick ratio
22.849
Management effectiveness
Return on assets (TTM)
-18.63%
Return on equity (TTM)
-29.57%
Valuation
Price to book
4.8
Price to tangible book (TTM)
4.8
Price to free cash flow (TTM)
-31.75
Growth
Earnings per share change (TTM)
71.87%
3-year earnings per share growth (CAGR)
0.71%
What the Analysts think about Nuvalent
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nuvalent stock.
Nuvalent Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Nuvalent Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Nuvalent News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nuvalent stock?
Nuvalent (NUVL) has a market cap of $5.4B as of January 22, 2025.
What is the P/E ratio for Nuvalent stock?
The price to earnings (P/E) ratio for Nuvalent (NUVL) stock is 0 as of January 22, 2025.
Does Nuvalent stock pay dividends?
No, Nuvalent (NUVL) stock does not pay dividends to its shareholders as of January 22, 2025.
When is the next Nuvalent dividend payment date?
Nuvalent (NUVL) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvalent?
Nuvalent (NUVL) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.